Tags

Type your tag names separated by a space and hit enter

Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial.
Int J Geriatr Psychiatry 2008; 23(12):1222-30IJ

Abstract

OBJECTIVES

Doubt over the cost-effectiveness of the cholinesterase inhibitors in dementia has renewed interest in alternative treatments such as Ginkgo biloba. We aimed to determine the effectiveness and the safety profile of Ginkgo biloba for treating early stage dementia in a community setting.

METHODS

We conducted a community-based, pragmatic, randomised, double-blind, parallel-group trial where participants were given a standardised extract of Ginkgo biloba (120 mg daily) or a placebo control for 6 months. Our primary outcomes were cognitive functioning (ADAS-Cog) and participant and carer-rated quality of life (QOL-AD).

RESULTS

We recruited 176 participants, mainly through general practices. In the ANCOVA model with baseline score as a co-variate (n = 176), Ginkgo did not have a significant effect on outcome at six months on either the ADAS-Cog score (p = 0.392), the participant-rated QOL-AD score (p = 0.787) nor the carer-rated QOL-AD score (p = 0.222).

CONCLUSION

We found no evidence that a standard dose of high purity Ginkgo biloba confers benefit in mild-moderate dementia over 6 months.

Authors+Show Affiliations

Department of Psychological Medicine, Imperial College London, UK. robmccarney@googlemail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

18537221

Citation

McCarney, Rob, et al. "Ginkgo Biloba for Mild to Moderate Dementia in a Community Setting: a Pragmatic, Randomised, Parallel-group, Double-blind, Placebo-controlled Trial." International Journal of Geriatric Psychiatry, vol. 23, no. 12, 2008, pp. 1222-30.
McCarney R, Fisher P, Iliffe S, et al. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry. 2008;23(12):1222-30.
McCarney, R., Fisher, P., Iliffe, S., van Haselen, R., Griffin, M., van der Meulen, J., & Warner, J. (2008). Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. International Journal of Geriatric Psychiatry, 23(12), pp. 1222-30. doi:10.1002/gps.2055.
McCarney R, et al. Ginkgo Biloba for Mild to Moderate Dementia in a Community Setting: a Pragmatic, Randomised, Parallel-group, Double-blind, Placebo-controlled Trial. Int J Geriatr Psychiatry. 2008;23(12):1222-30. PubMed PMID: 18537221.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. AU - McCarney,Rob, AU - Fisher,Peter, AU - Iliffe,Steve, AU - van Haselen,Robbert, AU - Griffin,Mark, AU - van der Meulen,Jan, AU - Warner,James, PY - 2008/6/10/pubmed PY - 2009/7/2/medline PY - 2008/6/10/entrez SP - 1222 EP - 30 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 23 IS - 12 N2 - OBJECTIVES: Doubt over the cost-effectiveness of the cholinesterase inhibitors in dementia has renewed interest in alternative treatments such as Ginkgo biloba. We aimed to determine the effectiveness and the safety profile of Ginkgo biloba for treating early stage dementia in a community setting. METHODS: We conducted a community-based, pragmatic, randomised, double-blind, parallel-group trial where participants were given a standardised extract of Ginkgo biloba (120 mg daily) or a placebo control for 6 months. Our primary outcomes were cognitive functioning (ADAS-Cog) and participant and carer-rated quality of life (QOL-AD). RESULTS: We recruited 176 participants, mainly through general practices. In the ANCOVA model with baseline score as a co-variate (n = 176), Ginkgo did not have a significant effect on outcome at six months on either the ADAS-Cog score (p = 0.392), the participant-rated QOL-AD score (p = 0.787) nor the carer-rated QOL-AD score (p = 0.222). CONCLUSION: We found no evidence that a standard dose of high purity Ginkgo biloba confers benefit in mild-moderate dementia over 6 months. SN - 1099-1166 UR - https://www.unboundmedicine.com/medline/citation/18537221/Ginkgo_biloba_for_mild_to_moderate_dementia_in_a_community_setting:_a_pragmatic_randomised_parallel_group_double_blind_placebo_controlled_trial_ L2 - https://doi.org/10.1002/gps.2055 DB - PRIME DP - Unbound Medicine ER -